Comparison of fluorescent single-strand conformation polymorphism analysis and denaturing high-performance liquid chromatography for detection of EXT1 and EXT2 mutations in hereditary multiple exostoses

EXT1 and EXT2 are two genes responsible for the majority of cases of hereditary multiple exostoses (HME), a dominantly inherited bone disorder. In order to develop an efficient screening strategy for mutations in these genes, we performed two independent blind screens of EXT1 and EXT2 in 34 unrelated patients with HME, using denaturing high-performance liquid chromatography (DHPLC) and fluorescent single-strand conformation polymorphism analysis (F-SSCP). The mutation likely to cause HME was found in 29 (85%) of the 34 probands: in 22 of these (76%), the mutation was in EXT1; seven patients (24%) had EXT2 mutations. Nineteen of these disease mutations have not been previously reported. Of the 42 different amplicon variants identified in total in the cohort, 40 were detected by DHPLC and 39 by F-SSCP. This corresponds to mutation detection efficiencies of 95% and 93% respectively. We have also found that we can confidently distinguish between different sequence variants in the same fragment using F-SSCP but not DHPLC. In light of this, and the similarly high sensitivities of the two techniques, we propose to continue screening with F-SSCP.

[1]  A. Monaco,et al.  Mutation screening of the EXT1 and EXT2 genes in patients with hereditary multiple exostoses. , 1997, American journal of human genetics.

[2]  D. Glavač,et al.  Optimization of the single‐strand conformation polymorphism (SSCP) technique for detection of point mutations , 1993, Human mutation.

[3]  E. Conrad,et al.  The natural history of hereditary multiple exostoses. , 1994, The Journal of bone and joint surgery. American volume.

[4]  M. Wagner,et al.  Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1) , 1995, Nature Genetics.

[5]  M. Wagner,et al.  Identification of novel mutations in the human EXT1 tumor suppressor gene , 1997, Human Genetics.

[6]  E. Wijsman,et al.  Evaluation of locus heterogeneity and EXT1 mutations in 34 families with hereditary multiple exostoses , 1998, Human mutation.

[7]  E. Conrad,et al.  Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses loci on chromosomes 8 and 11. , 1995, American journal of human genetics.

[8]  L. Liotta,et al.  Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. , 1994, Current opinion in oncology.

[9]  K. Yoshimoto,et al.  Multiple fluorescence-based PCR-SSCP analysis. , 1994, BioTechniques.

[10]  M. Lovett,et al.  The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes , 1996, Nature Genetics.

[11]  C. McCormick,et al.  The Putative Tumor Suppressors EXT1 and EXT2 Are Glycosyltransferases Required for the Biosynthesis of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.

[12]  B. D. de Vries,et al.  Positional cloning of a gene involved in hereditary multiple exostoses. , 1996, Human molecular genetics.

[13]  K. Hayashi,et al.  PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA. , 1991, PCR methods and applications.

[14]  T. Sekiya,et al.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Hennekam Hereditary multiple exostoses. , 1991, Journal of medical genetics.

[16]  B. D. de Vries,et al.  Refinement of the multiple exostoses locus (EXT2) to a 3-cM interval on chromosome 11. , 1995, American journal of human genetics.

[17]  L. Strong,et al.  Hereditary multiple exostoses (EXT): mutational studies of familial EXT1 cases and EXT-associated malignancies. , 1997, American journal of human genetics.

[18]  A. Munnich,et al.  A gene for hereditary multiple exostoses maps to chromosome 19p. , 1994, Human molecular genetics.

[19]  G. Mortier,et al.  Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses. , 1998, American journal of human genetics.

[20]  M. O’Donovan,et al.  Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection. , 1998, Genomics.

[21]  D. Gjerde,et al.  Detection of single-nucleotide polymorphisms with the WAVE DNA fragment analysis system. , 1997, Genetic testing.

[22]  L. Strong,et al.  Hereditary multiple exostosis and chondrosarcoma: linkage to chromosome II and loss of heterozygosity for EXT-linked markers on chromosomes II and 8. , 1995, American journal of human genetics.

[23]  B. D. de Vries,et al.  Assignment of a second locus for multiple exostoses to the pericentromeric region of chromosome 11. , 1994, Human molecular genetics.

[24]  T. Tahira,et al.  A streamlined mutation detection system: multicolor post-PCR fluorescence labeling and single-strand conformational polymorphism analysis by capillary electrophoresis. , 1997, Genome research.

[25]  V. Sheffield,et al.  The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. , 1993, Genomics.

[26]  D. Martindale,et al.  The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate , 1998, Nature Genetics.

[27]  B. Dworniczak,et al.  Comparison of conformation-sensitive gel electrophoresis and single-strand conformation polymorphism analysis for detection of mutations in the BRCA1 gene using optimized conformation analysis protocols , 1998, European Journal of Human Genetics.

[28]  I. Kremensky,et al.  Optimization of single-strand conformation polymorphism analysis in the presence of polyethylene glycol. , 1997, Clinical chemistry.

[29]  G. Schellenberg,et al.  Genetic heterogeneity in families with hereditary multiple exostoses. , 1993, American journal of human genetics.